Cancer: A Tough Opponent
Oasis of Hope Difference
Oxidizing Cancer to Death
Immune Stimulation Therapy
Nutaceuticals Cancer Control
Nutaceuticals Specific Cancers
Drugs for Cancer Control
Surgery and Radiation
Diet and Exercise
Caring for the Spirit
Contreras Metabolic Integrative Therapy (CMIT) Presentation
Nutrition for Cancer Prevention & Control
Diet for Health
Contreras Metabolic Integrative Therapy Research
Chapter 5: Oxidizing Cancer to Death
The chief way in which free radicals arise in a body's cells is by donation of an electron to molecular oxygen, generating a compound known as superoxide. This reaction can be catalyzed by several natural enzymatic reactions in cells. Superoxide can then, via spontaneous or enzyme-catalyzed reactions, give rise to other reactive compounds such as hydrogen peroxide or peroxynitrite. These compounds are not themselves free radicals, but they often give rise to free radicals, and they also can act to alter the structure and function of proteins by "oxidizing" them. Unsaturated fatty acids in membranes are also prone to oxidation by free radicals.
Because unabated damage by free radicals and oxidants can cause major and often adverse changes in the structures of cellular proteins and fats, living organisms have developed antioxidant mechanisms. Certain enzymes, as well as electron-donor molecules known as antioxidants, can "fix" free radicals by electron donation. This can work in other ways to prevent or undo the damage to biological molecule wrought by oxidant reactions. Examples include enzymes such as superoxide dismutase, catalase, glutathione peroxidase, and thioreductase, and antioxidant molecules such as glutathione and vitamins C and E. In normal healthy cellular metabolism, the production of oxidants is balanced by the action of antioxidant mechanisms that prevent free radical damage from getting out of hand and overwhelming the cell. But sometimes, either because of excess production of radicals and oxidants, or because of inadequately protective antioxidant mechanisms, free radical damage can get the upper hand - a condition known as "oxidant stress." Oxidant stress is not always bad. In fact, induction of oxidant stress is one way in which some cytotoxic drugs kill cancer cells. On the other hand, as we shall see, a constant moderate level of oxidant stress in some cancers renders them more aggressive and harder to kill.
A high proportion of cancers have low activity of the enzyme catalase, which degrades the oxidant chemical hydrogen peroxide (1-3). This adaptation may be beneficial to the cancer. Although oxidant chemicals can be toxic to cells, moderate increases in oxidant stress aid the growth and survival of many cancers (4-7). However, low catalase makes cancers potentially vulnerable to attack with hydrogen peroxide. Recently, researchers at the National Institutes of Health have discovered that high concentrations of vitamin C (ascorbate) can react spontaneously with molecular oxygen within tumors to generate large amounts of hydrogen peroxide, which can be lethal to tumor cells whose catalase activity is low (8,9). Such large concentrations can only be achieved by high dose intravenous infusions of vitamin C. Oral administration is ineffective in this regard (10). These findings rationalize several previous case reports of objective tumor regression in cancer patients treated repeatedly with high-dose intravenous vitamin C (11-13). Vitamin C is not toxic to normal healthy tissues because they have ample amounts of catalase activity. The current protocol insures that blood and tissue levels of vitamin C will remain high, with millimolar levels close to those of blood sugar for at least 4 hours.
However, it is not necessary to rely on unknown endogenous catalysts for this purpose. Certain small soluble organic molecules can perform the same catalytic function, expediting the transfer of electrons from ascorbate to oxygen. In particular, menadione, also known as vitamin K3, has this capacity (14). Menadione may be particularly appropriate for this purpose, as it has long been in clinical use as a source of vitamin K activity (15).
Moreover, there is substantial research literature demonstrating that joint incubation with sodium ascorbate and menadione is often selectively toxic to cancer cells. This phenomenon has been demonstrated with a wide range of human and rodent cancer (16-20). In striking parallel to the studies which report that high concentrations of ascorbate alone can exert such toxicity, it has been shown that concurrent incubation with the enzyme catalase – which destroys hydrogen peroxide – markedly alleviates this toxicity, demonstrating that hydrogen peroxide mediates this cancer-killing effect. Furthermore, cancer cells which express relatively low levels of catalase are more susceptible to this toxicity than cancer cells with higher levels of this activity. The selective susceptibility of cancer cells, as contrasted to normal cells, reflects the tendency of cancers to have lower levels of catalase and other enzymes which dispose of hydrogen peroxide (14,21). This, in turn, may reflect the fact that low concentrations of hydrogen peroxide promote cellular proliferation and survival in many cancers. In other words, low catalase activity, by enabling cancers to sustain modest concentrations of hydrogen peroxide, may make some cancers more aggressive and viable (21) – that is, until they are assaulted with high concentrations of ascorbate.
Researchers at the Catholic University of Louvain, Belgium, have played a pioneering role in demonstrating the potential utility of ascorbate/menadione in cancer therapy. In particular, they have shown that injection, or even oral administration of these agents, can retard cancer growth and metastasis in tumor-bearing rodents (14,22,23). They report that this therapy is well tolerated, without any evident damage to healthy tissues, and they recommend that this strategy should be assessed in clinical trials. They also demonstrate that ascorbate/menadione can interact synergistically with certain cytotoxic chemotherapy drugs in killing cancer cells, presumably because a concurrent increase in oxidant stress can make these drugs more lethal (24). This observation has been independently confirmed (25). Indeed, there are reports that menadione alone can potentiate the cytotoxicity of certain chemotherapy agents, presumably because, in sufficiently high concentrations, intracellular menadione can generate oxidant stress by transferring electrons from intracellular molecules to oxygen (26,27).
Since injectible vitamin K3 has long been clinically available in Mexico, we now administer this vitamin just prior to the vitamin C infusions. It is our hope and expectation that inclusion of menadione in the ascorbate infusions will markedly potentiate generation of hydrogen peroxide in tumors, enabling a more substantial cell kill in those cancers that are sufficiently low in catalase activity.
At Oasis of Hope, O3-AHT is used not only in conjunction with chemotherapy, but also with high-dose intravenous sodium ascorbate therapy for CMIT-C. This strategy involves drawing 200 ml of a patient's blood, treating it with a mixture of ozone and oxygen, and re-infusing it. This procedure is typically repeated several times weekly. It is important to stress that Oasis of Hope employs an O3-AHT protocol that has been widely utilized in Europe for decades with an excellent safety record. The safety of this strategy reflects the fact that no ozone is infused into the body. Ozone is very unstable, and for practical purposes is completely dissipated before the ozone-treated blood is returned to the body. Thus, the body is exposed to ozone oxidation products, rather than ozone itself. Exposure of blood to ozone in clinically appropriate amounts does not cause lysis of red blood cells, or compromise the functional viability of white cells. No evident side effects are noted in patients receiving O3-AHT.
Oasis of Hope also has a novel perfluorochemical emulsion known as Perftec that is an oxygen carrier. When infused into a patient, it greatly boosts the total oxygen carrying capacity of blood (31). After Perftec infusion, patients are asked to breathe air that is enriched in oxygen content, so that the circulating Perftec is loaded with optimal amounts of oxygen. The combination of ozone autohemotherapy and Perftec infusion can be expected to improve oxygen availability in hypoxic regions of tumors. This in turn should boost the ability of intravenous ascorbate and vitamin K to generate hydrogen peroxide in tumors.
Although many patients will be treated with chemotherapy, some will not. In some cases, the type of cancer is known to be resistant to available chemotherapy drugs. In other cases, patients elect to forego chemotherapy for personal reasons. For these patients, it is hoped that a vitamin C & K3/tumor oxygenation regimen will be sufficient to achieve worthwhile destruction of the tumor.
Prior to receiving vitamin K3 and vitamin C (and possibly chemotherapy), patients are also supplemented with the nutrient selenium and the herb silymarin, which is a source of the natural anti-inflammatory compound silibinin. Like salicylate, these agents have potential for sensitizing tumors to destruction by chemotherapy or oxidant stress. Silymarin's activity in this regard may be similar to salicylate's. It suppresses activation of NF-kappaB (47,48). Recent studies show that high doses of organic selenium can make cancer cells more sensitive to many types of chemotherapeutic drugs (49). There are reasons to believe that selenium may also make hydrogen peroxide more lethal to tumors. We now administer selenium in a form known as methylselenocysteine (MSC), which is a natural organic form found in certain foods. MSC is the preferable form for this application because it is rapidly metabolized to release the organic selenium metabolites useful in cancer therapy.
We also will be exploring the use of activated vitamin D (calcitriol) as a chemosensitizing agent in cancer therapy. Calcitriol appears to be quite safe if administered in only one or two doses a week, and if the concurrent diet is relatively low in calcium (50). Calcitriol has been shown to boost the sensitivity of many cancers to chemotherapy drugs or hydrogen peroxide (51,52).
During their stay at Oasis of Hope Hospital, patients will also be supplemented with various nutrients such as fish oil, green tea polyphenols, and melatonin. The purpose is to slow tumor growth by blocking new blood vessel formation (angiogenesis) or boosting the body's immune capacities. Supplementation with these nutrients will continue after patients return home between hospital therapy sessions. This "after-therapy" can be crucial for improving chances of a cure or at least achieving a worthwhile prolongation of high-quality life.
1. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med
2. Kwei KA, Finch JS, Thompson EJ, Bowden GT. Transcriptional repression of
3. Tas F, Hansel H, Belce A, Ilvan S, Argon A, Camlica H, Topuz E. Oxidative stress in
4. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy
5. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive
6. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L, Petros JA, Arnold
7. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy
8. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E,
9. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput
10. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine
11. Padayatty SJ, Levine M. Reevaluation of ascorbate in cancer treatment: emerging
12. Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, Taylor
13. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously
14. Calderon PB, Cadrobbi J, Marques C, Hong-Ngoc N, Jamison JM, Gilloteaux J,
15. Sharma RK, Marwaha N, Kumar P, Narang A. Effect of oral water soluble vitamin
16. Venugopal M, Jamison JM, Gilloteaux J, Koch JA, Summers M, Giammar D,
17. Gilloteaux J, Jamison JM, Neal DR, Summers JL. Cell death by autoschizis in
18. Zhang W, Negoro T, Satoh K, Jiang Y, Hashimoto K, Kikuchi H, Nishikawa H,
19. Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, Summers JL, Taper HS,
20. Gilloteaux J, Jamison JM, Arnold D, Neal DR, Summers JL. Morphology and DNA
21. McCarty MF, Barroso-Aranda J, Contreras F. A two-phase strategy for treatment of
22. Verrax J, Stockis J, Tison A, Taper HS, Calderon PB. Oxidative stress by ascorbate/
23. Taper HS, Jamison JM, Gilloteaux J, Summers JL, Calderon PB. Inhibition of the
24. De LW, Janssens J, Bonte J, Taper HS. Effects of sodium ascorbate (vitamin C)
25. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and
26. Tetef M, Margolin K, Ahn C, Akman S, Chow W, Coluzzi P, Leong L, Morgan RJ,
27. Tetef M, Margolin K, Ahn C, Akman S, Chow W, Leong L, Morgan RJ, Jr., Raschko
28. Giunta R, Coppola A, Luongo C, Sammartino A, Guastafierro S, Grassia A,
29. Clavo B, Perez JL, Lopez L, Suarez G, Lloret M, Rodriguez V, Macias D, Santana M,
30. Bocci V, Larini A, Micheli V. Restoration of normoxia by ozone therapy may
31. Verdin-Vasquez RC, Zepeda-Perez C, Ferra-Ferrer R, Chavez-Negrete A, Contreras
32. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E,
33. Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B,
34. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Resistance to paclitaxel
35. Chan MM, Soprano KJ, Weinstein K, Fong D. Epigallocatechin-3-gallate delivers
36. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994
37. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA,
38. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C,
39. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin.
41. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004
42. Cusack JC, Liu R, Baldwin AS. NF- kappa B and chemoresistance: potentiation
43. Whittle BJ, Hansen D, Salmon JA. Gastric ulcer formation and cyclo-oxygenase
44. Zambraski EJ, Atkinson DC, Diamond J. Effects of salicylate vs. aspirin on renal
45. Boettcher FA, Salvi RJ. Salicylate ototoxicity: review and synthesis. Am J
46. McPherson TC. Salsalate for arthritis: a clinical evaluation. Clin Ther
47. Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC,
48. Flaig TW, Su LJ, Harrison G, Agarwal R, Glode LM. Silibinin synergizes with
49. Fakih M, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity
50. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol
51. Weitsman GE, Koren R, Zuck E, Rotem C, Liberman UA, Ravid A. Vitamin D
52. Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A. Vitamin D is a
Why choose Oasis of hope?
Stage IV Alternative cancer Treatment Options
Become a Patient
Cancer Support Program
Cancer Survivor's Stories
Oasis of Hope Difference
Immune Stimulation Therapy
Surgery and Radiation
Cell Redox Regulatory Therapy
Immune Stimulation Therapy
Signal Transduction Therapy
Diet and Excercise